CHICAGO, Nov. 27—Cleveland Clinic Foundation and Riverain Medical have begun an ongoing clinical trial to determine whether chest x-ray computer-aided detection (CAD) can improve practical early detection of lung cancer, which the companies announced at the 93rd annual meeting of the Radiological Society of North America (RSNA).
The program is designed to determine whether chest x-ray CAD can help identify hard to detect lung cancers at an early stage when they are most treatable, leading to improved patient survival rates, according to the Miamisburg, Ohio-based Riverain.
“Developing early detection methods is a key to improving treatment of lung cancer,” said Michael Phillips, MD, section head of imaging sciences in Cleveland Clinic’s department of diagnostic radiology. “As it stands now, treatment options are limited because identifying malignant lung tumors in their early stage is so difficult.”
The study, funded state of Ohio grant will involve 9,000 test subjects, and will consist of a five-year follow-up. Moulay Meziane, MD, the principal investigator and colleagues are currently conducting retrospective studies to evaluate the performance of the CAD system and its readers. The participants for the study will be enrolled in early 2008.
Statistically, lung cancer kills more people in the United States annually than breast, prostate and colon cancers combined. Eighty million chest x-rays are taken each year for a variety of reasons, and without chest x-ray CAD, many lung cancers may not be found or are overlooked when lung cancer is most treatable, Riverain reported.
The Cleveland Clinic and Riverain jointly said that Wright State University and University Hospitals Health System also have joined together to form the Early Lung Disease Detection Alliance, a multidisciplinary research and commercialization program that will develop, clinically test and bring to market new image-analysis systems that permit the early detection of lung cancer and other lung diseases.